Sertindole (BioDeep_00000006540)

 

Secondary id: BioDeep_00001868194

human metabolite blood metabolite


代谢物信息卡片


1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone

化学式: C24H26ClFN4O (440.1779)
中文名称: 舍吲哚
谱图信息: 最多检出来源 Homo sapiens(blood) 73.71%

分子结构信息

SMILES: C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
InChI: InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)

描述信息

Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist
C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells[1][2][3].

同义名列表

11 个代谢物同义名

1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one; 1-[2-[4-[5-Chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one; Sertindole hydrochloride; Sertindolum; SERTINDOLE; Serdolect; Sertindol; SerLect; Lu 23-174; Sertindole



数据库引用编号

16 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 8 ADRA1A, CACNA1A, CAT, CYP2B6, CYP2D6, CYP3A4, SOD1, STAT3
Peripheral membrane protein 1 CYP2B6
Endoplasmic reticulum membrane 5 CYP1A2, CYP2B6, CYP2D6, CYP3A4, DRD1
Nucleus 5 ADRA1A, CACNA1A, DRD1, SOD1, STAT3
cytosol 5 ADRA1A, CAT, GSR, SOD1, STAT3
dendrite 5 DRD2, HTR1A, HTR2A, HTR2C, HTR6
nucleoplasm 3 ADRA1A, SOD1, STAT3
RNA polymerase II transcription regulator complex 1 STAT3
Cell membrane 9 ADRA1A, CACNA1A, DRD1, DRD2, HTR1A, HTR2A, HTR2C, HTR6, KCNH2
Cell projection, axon 1 HTR2A
Multi-pass membrane protein 11 ADRA1A, CACNA1A, DRD1, DRD2, HTR1A, HTR2A, HTR2C, HTR6, KCNA3, KCNH2, NNT
Golgi apparatus membrane 1 DRD2
Synapse 5 CACNA1A, DRD2, HTR1A, HTR2C, HTR6
cell surface 1 KCNH2
dendritic shaft 1 HTR2A
glutamatergic synapse 4 DRD1, DRD2, HTR2A, KCNA3
Golgi membrane 2 DRD2, INS
mitochondrial inner membrane 1 NNT
neuronal cell body 3 CACNA1A, HTR2A, SOD1
presynaptic membrane 4 DRD1, DRD2, HTR2A, KCNA3
Presynapse 1 HTR2A
acrosomal vesicle 1 DRD2
plasma membrane 11 ADRA1A, CACNA1A, DRD1, DRD2, HTR1A, HTR2A, HTR2C, HTR6, KCNA3, KCNH2, STAT3
synaptic vesicle membrane 1 DRD2
Membrane 7 CACNA1A, CAT, CYP2D6, CYP3A4, KCNA3, KCNH2, NNT
axon 3 DRD2, HTR2A, KCNA3
caveola 2 ADRA1A, HTR2A
extracellular exosome 3 CAT, GSR, SOD1
endoplasmic reticulum 1 CYP2D6
extracellular space 2 INS, SOD1
perinuclear region of cytoplasm 2 KCNA3, KCNH2
mitochondrion 5 CAT, CYP2D6, GSR, NNT, SOD1
protein-containing complex 2 CAT, SOD1
intracellular membrane-bounded organelle 6 ADRA1A, CAT, CYP1A2, CYP2B6, CYP2D6, CYP3A4
Microsome membrane 4 CYP1A2, CYP2B6, CYP2D6, CYP3A4
Secreted 1 INS
extracellular region 3 CAT, INS, SOD1
Single-pass membrane protein 1 CYP2D6
mitochondrial matrix 3 CAT, GSR, SOD1
transcription regulator complex 1 STAT3
ciliary membrane 2 DRD1, DRD2
Nucleus membrane 1 ADRA1A
nuclear membrane 1 ADRA1A
external side of plasma membrane 1 GSR
dendritic spine 2 DRD1, DRD2
perikaryon 1 DRD2
cytoplasmic vesicle 2 HTR2A, SOD1
axon cytoplasm 1 SOD1
postsynaptic membrane 4 DRD1, DRD2, HTR2A, KCNA3
Mitochondrion inner membrane 1 NNT
Matrix side 1 NNT
Membrane raft 1 KCNA3
focal adhesion 1 CAT
GABA-ergic synapse 2 DRD1, DRD2
Peroxisome 2 CAT, SOD1
Peroxisome matrix 1 CAT
peroxisomal matrix 1 CAT
peroxisomal membrane 1 CAT
Cell projection, dendritic spine 1 DRD1
mitochondrial intermembrane space 1 SOD1
lateral plasma membrane 1 DRD2
dendrite cytoplasm 1 SOD1
cilium 3 DRD1, DRD2, HTR6
chromatin 1 STAT3
cell projection 1 CACNA1A
non-motile cilium 2 DRD1, DRD2
[Isoform 2]: Cell membrane 1 KCNA3
sperm flagellum 1 DRD2
endosome lumen 1 INS
Membrane, caveola 2 ADRA1A, HTR2A
monoatomic ion channel complex 2 CACNA1A, KCNH2
cell body fiber 1 HTR2A
Cell projection, dendrite 3 DRD1, HTR1A, HTR2A
respiratory chain complex 1 NNT
inward rectifier potassium channel complex 1 KCNH2
voltage-gated potassium channel complex 2 KCNA3, KCNH2
ficolin-1-rich granule lumen 1 CAT
secretory granule lumen 2 CAT, INS
Golgi lumen 1 INS
endoplasmic reticulum lumen 1 INS
axon terminus 1 DRD2
voltage-gated calcium channel complex 1 CACNA1A
endocytic vesicle 1 DRD2
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
neurofilament 1 HTR2A
calyx of Held 1 KCNA3
[Isoform 1]: Cell membrane 1 KCNA3
dopaminergic synapse 1 DRD2
Cell projection, cilium membrane 1 DRD1
catalase complex 1 CAT
G protein-coupled receptor complex 2 DRD1, DRD2
[Isoform 3]: Cytoplasm, perinuclear region 1 KCNA3
G protein-coupled serotonin receptor complex 2 HTR2A, HTR2C


文献列表

  • I P Remezova, D S Lazarian, A V Voronkov, N S Avramenko, T I Maksimenko, D Iu Sanzhieva. [The chemical toxicological analysis of sertindole]. Sudebno-meditsinskaia ekspertiza. 2016 Jan; 59(1):35-39. doi: 10.17116/sudmed201659135-39. [PMID: 27030096]
  • Aleksandra Nikolić-Kokić, Ana Mijušković, Nikola Tatalović, Jelena Nestorov, Marko Miler, Zorana Oreščanin-Dušić, Milan Nikolić, Verica Milošević, Duško Blagojević, Mihajlo Spasić, Čedo Miljević. Effects of antipsychotic drug administration on antioxidative defense enzymes in male rat kidney. Journal of toxicology and environmental health. Part A. 2016; 79(20):905-11. doi: 10.1080/15287394.2016.1201706. [PMID: 27644343]
  • Liang Guo, Luke Coyle, Rory M C Abrams, Raymond Kemper, Eric T Chiao, Kyle L Kolaja. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicological sciences : an official journal of the Society of Toxicology. 2013 Dec; 136(2):581-94. doi: 10.1093/toxsci/kft205. [PMID: 24052561]
  • Anu J Airaksinen, Sjoerd J Finnema, Thomas Balle, Katarina Varnäs, Benny Bang-Andersen, Balázs Gulyás, Lars Farde, Christer Halldin. Radiosynthesis and evaluation of new α1-adrenoceptor antagonists as PET radioligands for brain imaging. Nuclear medicine and biology. 2013 Aug; 40(6):747-54. doi: 10.1016/j.nucmedbio.2013.05.007. [PMID: 23810488]
  • A Brunnauer, G Laux. Driving ability under sertindole. Pharmacopsychiatry. 2012 Mar; 45(2):47-50. doi: 10.1055/s-0031-1287781. [PMID: 21989603]
  • Tim Moons, Mariska de Roo, Stephan Claes, Geert Dom. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011 Aug; 12(8):1193-211. doi: 10.2217/pgs.11.55. [PMID: 21843066]
  • Marc De Hert, Aurélia Mittoux, Yuan He, Joseph Peuskens. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. European archives of psychiatry and clinical neuroscience. 2011 Jun; 261(4):231-9. doi: 10.1007/s00406-010-0142-x. [PMID: 20820795]
  • Guido Gessner, Regina Macianskiene, John G Starkus, Roland Schönherr, Stefan H Heinemann. The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism. European journal of pharmacology. 2010 Apr; 632(1-3):52-9. doi: 10.1016/j.ejphar.2010.01.010. [PMID: 20097192]
  • Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira. Safety and tolerability of antipsychotics: focus on amisulpride. Drug, healthcare and patient safety. 2010; 2(?):205-11. doi: 10.2147/dhps.s6226. [PMID: 21701632]
  • V Kerna, G Nosalova, I Ondrejka. Metabolic risk in selected second-generation antipsychotics. Bratislavske lekarske listy. 2010; 111(12):640-3. doi: . [PMID: 21384731]
  • Eva Choong, Serge Rudaz, Astrid Kottelat, Davy Guillarme, Jean-Luc Veuthey, Chin B Eap. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. Journal of pharmaceutical and biomedical analysis. 2009 Dec; 50(5):1000-8. doi: 10.1016/j.jpba.2009.07.007. [PMID: 19683888]
  • R Miller. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Current neuropharmacology. 2009 Dec; 7(4):315-30. doi: 10.2174/157015909790031184. [PMID: 20514211]
  • Viktoria Simon, Ruud van Winkel, Marc De Hert. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. The Journal of clinical psychiatry. 2009 Jul; 70(7):1041-50. doi: 10.4088/jcp.08r04392. [PMID: 19653979]
  • Christoffer Bundgaard, Frank Larsen, Mads Kreilgaard, Lise T Brennum, Christina Kurre Olsen. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. Biopharmaceutics & drug disposition. 2009 May; 30(4):209-20. doi: 10.1002/bdd.656. [PMID: 19475539]
  • Linda Hanssens, Gilbert L'Italien, Jean-Yves Loze, Ronald N Marcus, Miranda Pans, Wendy Kerselaers. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC psychiatry. 2008 Dec; 8(?):95. doi: 10.1186/1471-244x-8-95. [PMID: 19102734]
  • Edoardo Spina, Rocco Zoccali. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert opinion on drug metabolism & toxicology. 2008 May; 4(5):629-38. doi: 10.1517/17425255.4.5.629. [PMID: 18484920]
  • Christina Kurre Olsen, Lise Tøttrup Brennum, Mads Kreilgaard. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. European journal of pharmacology. 2008 Apr; 584(2-3):318-27. doi: 10.1016/j.ejphar.2008.02.005. [PMID: 18325493]
  • Pierre Chue. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatric disease and treatment. 2007 Feb; 3(1):13-39. doi: 10.2147/nedt.2007.3.1.13. [PMID: 19300536]
  • Massimo C Mauri, Lucia S Volonteri, Alessandro Colasanti, Alessio Fiorentini, Ilaria F De Gaspari, Silvio R Bareggi. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clinical pharmacokinetics. 2007; 46(5):359-88. doi: 10.2165/00003088-200746050-00001. [PMID: 17465637]
  • Edoardo Spina, Jose de Leon. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic & clinical pharmacology & toxicology. 2007 Jan; 100(1):4-22. doi: 10.1111/j.1742-7843.2007.00017.x. [PMID: 17214606]
  • Eva Lindström, Sten Levander. Sertindole: efficacy and safety in schizophrenia. Expert opinion on pharmacotherapy. 2006 Sep; 7(13):1825-34. doi: 10.1517/14656566.7.13.1825. [PMID: 16925508]
  • Michael Didriksen, Mads Kreilgaard, Jørn Arnt. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. European journal of pharmacology. 2006 Aug; 542(1-3):108-15. doi: 10.1016/j.ejphar.2006.05.021. [PMID: 16806167]
  • Mireille Canal-Raffin, Karine Titier, Evelyne Déridet, Béatrice Martinez, Abdelilah Abouelfath, Alain Miras, Sophie Gromb, Mathieu Molimard, Nicholas Moore. Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs. Biopharmaceutics & drug disposition. 2006 May; 27(4):171-9. doi: 10.1002/bdd.490. [PMID: 16419145]
  • Alexander N Katchman, John Koerner, Toshimasa Tosaka, Raymond L Woosley, Steven N Ebert. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. The Journal of pharmacology and experimental therapeutics. 2006 Mar; 316(3):1098-106. doi: 10.1124/jpet.105.093393. [PMID: 16278312]
  • Robert D Oades, Bernd Röpcke, Uwe Henning, Ansgard Klimke. Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity. Behavioral and brain functions : BBF. 2005 Aug; 1(?):14. doi: 10.1186/1744-9081-1-14. [PMID: 16091141]
  • Mireille Canal-Raffin, Evelyne Déridet, Karine Titier, Eric Frakra, Mathieu Molimard, Nicholas Moore. Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 Jan; 814(1):61-7. doi: 10.1016/j.jchromb.2004.10.020. [PMID: 15607708]
  • Karine Titier, Pierre-Olivier Girodet, Hélène Verdoux, Mathieu Molimard, Bernard Bégaud, Wilhelm Haverkamp, Malcolm Lader, Nicholas Moore. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug safety. 2005; 28(1):35-51. doi: 10.2165/00002018-200528010-00003. [PMID: 15649104]
  • Karine Titier, Mireille Canal, Evelyne Déridet, Abdelilah Abouelfath, Sophie Gromb, Mathieu Molimard, Nicholas Moore. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicology and applied pharmacology. 2004 Aug; 199(1):52-60. doi: 10.1016/j.taap.2004.03.016. [PMID: 15289090]
  • S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville, T Fischer. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer. 2003 Nov; 89(10):1855-9. doi: 10.1038/sj.bjc.6601152. [PMID: 14612892]
  • Morten B Thomsen, Paul G A Volders, Milan Stengl, Roel L H M G Spätjens, Jet D M Beekman, Ulrike Bischoff, Morten A Kall, Kristen Frederiksen, Jørgen Matz, Marc A Vos. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. The Journal of pharmacology and experimental therapeutics. 2003 Nov; 307(2):776-84. doi: 10.1124/jpet.103.052753. [PMID: 12966159]
  • Fabien Trémeau, Leslie Citrome. Optimizing dosing in atypical neuroleptic monotherapy. Dialogues in clinical neuroscience. 2002 Dec; 4(4):438-43. doi: 10.31887/dcns.2002.4.4/ftremeau. [PMID: 22033705]
  • R Berecz, A de la Rubia Martínez, M J Norberto Gamero, J R Gutiérrez Casares, T Glaub, I Degrell, A Llerena. [Relationship between clozapine plasma levels and withdrawal symptoms]. Actas espanolas de psiquiatria. 2002 Nov; 30(6):397-9. doi: NULL. [PMID: 12487951]
  • T Baptista, N M K N Y Kin, S Beaulieu, E A de Baptista. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002 Nov; 35(6):205-19. doi: 10.1055/s-2002-36391. [PMID: 12518268]
  • Sathapana Kongsamut, Jiesheng Kang, Xiao-Liang Chen, Joachim Roehr, David Rampe. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002 Aug; 450(1):37-41. doi: 10.1016/s0014-2999(02)02074-5. [PMID: 12176106]
  • Philip Seeman. Atypical antipsychotics: mechanism of action. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2002 Feb; 47(1):27-38. doi: . [PMID: 11873706]
  • G A Gintant, J T Limberis, J S McDermott, C D Wegner, B F Cox. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. Journal of cardiovascular pharmacology. 2001 May; 37(5):607-18. doi: 10.1097/00005344-200105000-00012. [PMID: 11336111]
  • K Sakai, X M Gao, T Hashimoto, C A Tamminga. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse (New York, N.Y.). 2001 Feb; 39(2):152-60. doi: 10.1002/1098-2396(200102)39:2<152::aid-syn6>3.0.co;2-f. [PMID: 11180502]
  • S Kapur, G Remington. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annual review of medicine. 2001; 52(?):503-17. doi: 10.1146/annurev.med.52.1.503. [PMID: 11160792]
  • S L Wong, G Cao, R J Mack, G R Granneman. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. Journal of clinical pharmacology. 1997 Nov; 37(11):1056-61. doi: 10.1002/j.1552-4604.1997.tb04287.x. [PMID: 9505999]
  • M Ipsen, Y Zhang, N Dragsted, C Han, M J Mulvany. The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries. European journal of pharmacology. 1997 Oct; 336(1):29-35. doi: 10.1016/s0014-2999(97)01242-9. [PMID: 9384251]
  • J J Sramek, R J Mack, W Awni, J Hourani, S S Jhee, S Barto, N R Cutler. Two rapid-dose titrations of sertindole in patients with schizophrenia. Journal of clinical psychopharmacology. 1997 Oct; 17(5):419-22. doi: 10.1097/00004714-199710000-00011. [PMID: 9315993]
  • S L Wong, G Cao, R J Mack, G R Granneman. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clinical pharmacology and therapeutics. 1997 Aug; 62(2):157-64. doi: 10.1016/s0009-9236(97)90063-1. [PMID: 9284851]
  • Y Y Zhang, Z Z Lu, H Wei, Q D Han. [Sertindole, a novel alpha 1A-adrenoceptor selective antagonist]. Yao xue xue bao = Acta pharmaceutica Sinica. 1997 Jul; 32(7):490-5. doi: . [PMID: 11596272]
  • P Seeman, R Corbett, H H Van Tol. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1997 Feb; 16(2):93-110; discussion 111. doi: 10.1016/s0893-133x(96)00187-x. [PMID: 9015795]
  • S L Wong, S Menacherry, D Mulford, P J Schmitz, C Locke, G R Granneman. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. European journal of clinical pharmacology. 1997; 52(3):223-7. doi: 10.1007/s002280050278. [PMID: 9218930]
  • K Sakamoto, Y Nakamura, S Aikoh, T Baba, J Perregaard, H Pedersen, E K Moltzen, D J Mulford, T Yamaguchi. Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica; the fate of foreign compounds in biological systems. 1995 Dec; 25(12):1327-43. doi: 10.3109/00498259509061921. [PMID: 8719908]
  • T B Tzeng, G Stamm, S Y Chu. Sensitive method for the assay of sertindole in plasma by high-performance liquid chromatography and fluorimetric detection. Journal of chromatography. B, Biomedical applications. 1994 Nov; 661(2):299-306. doi: 10.1016/0378-4347(94)00356-4. [PMID: 7894670]